CompletedNCT02527564
Suvorexant for Insomnia in People With Bipolarity
About this title
Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder
Read the official source — NCT02527564Medication studyAges 18+United States
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- StanfordSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateSeptember 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 61
- Sponsor
- Stanford University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT02527564
- Official title
Show the full official title
A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Suvorexant for Treatment-resistant Insomnia in Patients With Bipolar Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Stanford
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Stanford University, a university.
Did this study involve medication?
Yes. The study involved medication, including Suvorexant and Placebo.
Who was this study for?
Listed age limits: from 18 years.
